ADAG
HealthcareAdagene Inc.
$1.78
$-0.06 (-3.26%)
Jan 5, 2026
Price History (1Y)
Analysis
Adagene Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $83.89M and 138 employees. The company's revenue for the trailing twelve months (TTM) stands at $103,204. The financial health of Adagene Inc. indicates a significant loss, with a net income of -$29,889,636 for the TTM period. The operating margin is -32,283.6%, and the profit margin is 0.0%. Returns on equity (ROE) are -63.3%, while returns on assets (ROA) are -24.9%. The company's balance sheet shows a debt-to-equity ratio of 18.07 and a cash position of $62.83M, with debt totaling $6.85M. Adagene Inc.'s valuation is characterized by a forward P/E ratio of -2.47 and a price to book ratio of 2.21. The company's price to sales ratio is 812.89, while the EV/EBITDA ratio is -1.60. The 52-week high for the stock was $3.16, with a low of $1.30.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Adagene Inc.
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Visit website →Key Statistics
- Market Cap
- $83.89M
- P/E Ratio
- N/A
- 52-Week High
- $3.16
- 52-Week Low
- $1.30
- Avg Volume
- 128.07K
- Beta
- 0.72
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- China
- Employees
- 138